Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic cancers. Two types of receptor systems have been used to redirect the activity of T cells, normal heterodimeric T-cell receptors (TCRs) or synthetic chimeric antigen receptors (CARs). TCRs recognize peptide-HLA complexes whereas CARs typically use an antibody-derived scFv (single-chain fragments variable) that recognizes cancer-associated cell-surface antigens. While both receptors mediate diverse effector functions, a quantitative comparison of the sensitivity and signaling capacity of TCRs and CARs has been limited due to their differences in affinities and ligands. Here we describe their direct comparison by using TCRs that could be format...
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tum...
Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-ce...
This study compared second-generation chimeric antigen receptors (CAR) encoding signaling domains co...
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic ...
Adoptive Cell Therapy (ACT) is a novel approach to cancer treatment, which implements the use of the...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
© 2014 Dr. Connie DuongAdoptive immunotherapy is a promising treatment for cancer, with response rat...
T-cell receptors (TCR) recognize intracellular and extracellular cancer antigens, allowing T cells t...
T cell-based immunotherapy has demonstrated great therapeutic potential in recent decades, on the on...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
Chimeric antigen receptors (CARs) are versatile synthetic receptors that provide T cells with engine...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets hav...
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tum...
Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-ce...
This study compared second-generation chimeric antigen receptors (CAR) encoding signaling domains co...
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic ...
Adoptive Cell Therapy (ACT) is a novel approach to cancer treatment, which implements the use of the...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
© 2014 Dr. Connie DuongAdoptive immunotherapy is a promising treatment for cancer, with response rat...
T-cell receptors (TCR) recognize intracellular and extracellular cancer antigens, allowing T cells t...
T cell-based immunotherapy has demonstrated great therapeutic potential in recent decades, on the on...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
Chimeric antigen receptors (CARs) are versatile synthetic receptors that provide T cells with engine...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets hav...
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tum...
Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-ce...
This study compared second-generation chimeric antigen receptors (CAR) encoding signaling domains co...